Inovio Pharmaceuticals announced Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate cancer, as well as their research collaboration in prostate cancer.
All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned to Inovio.
Inovio plans to independently advance INO-5150 into a phase I clinical trial in the first half of 2015.
Inovio and Roche will continue to collaborate and co-develop Inovio's DNA immunotherapy (INO-1800) against hepatitis B virus under their existing license agreement. The partnership is on track to move INO-1800 collaboratively into a phase I study in 2015.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends